MedX Health Announces That Dr. Bruno Battistini, an Accomplished Canadian-Based Health Care Researcher Has Joined Its Medical Advisory Board
MISSISSAUGA, Ontario–(BUSINESS WIRE)—December 27, 2018
MedX Health Corp. (“MedX”) (MDX.V) announced today that Dr. Bruno Battistini, a Canadian-based health care researcher and medical business advisor has joined MedX’s Medical Advisory Board.
“While the members of our Medical Advisory Board to date are esteemed physicians and researchers specializing in skin cancer and other Dermatological conditions, Dr. Battistini complements the group by providing a breadth of experience dealing with policy, and bridging the gap with government, health care agencies and providers to gain access to Canadian markets,” said Scott Spearn, CEO of MedX. “His understanding of the dynamics in the Private/Public market will be of great benefit as we launch our skin assessment platform, DermSecure™, across Canada.”
“I am genuinely impressed with MedX’s complete solution for skin cancer screening,” noted Dr. Battistini. “Not only is the scanning technology so unique, offering the ability to image and highlight pathophysiology images below the skin, but the development of an internet-based platform that can provide widespread access to the public for fast and easy assessment will be a driver for reducing wait times and improved outcomes in a world that is experiencing increasing incidence of skin cancer and other skin conditions. There is no reason why MedX’s technology cannot assist our health care system and streamline the services to meet patients’ needs when it has already been implemented in other countries and working successfully for many years. The translation of knowledge and implementation of innovation is key to the sustainability of our healthcare system, considering our aging population,” noted Dr. Battistini
Dr. Battistini is an accomplished health care researcher, former professor of medicine, entrepreneur, senior executive and administrator whose background in pharmacology has resulted in a broad range of experience working with universities, government agencies and health foundations to understand how policies are developed such that companies can access markets with innovative products to improve the health care system and benefit patients and the general population. He has engaged with many Canadian companies, all in major and smaller provinces in guiding the development, acknowledgement, adoption and commercializing of products.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181227005290/en/
Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229